On the stock market since 1997, it operates in the world of health and science. It has 41 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 8% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 45% below its peak. The market has trimmed its expectations for the company.
Sales run at $13.1M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 11 buys and 1 sell. Management buying with its own money is usually read as a good sign.
A loss of $908K against $13.1M in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.07. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
On our five-subject report card, INIS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: INIS is a high-risk stock — not yet profitable, and its future rides on its product catching on.